Cargando…

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION

Detalles Bibliográficos
Autores principales:	Charilaou, Paris, Tricarico, Christopher, Battat, Robert, Scherl, Ellen J., Longman, Randy, Lukin, Dana J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212469/ http://dx.doi.org/10.1016/S0016-5085(22)61409-4

Ejemplares similares

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination
por: Charilaou, Paris, et al.
Publicado: (2022)

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease
por: Gordon, Benjamin Langan, et al.
Publicado: (2022)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD
por: Lukin, Dana J., et al.
Publicado: (2021)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
por: Lukin, Dana J., et al.
Publicado: (2020)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022)

Predicting inpatient mortality in patients with inflammatory bowel disease: A machine learning approach
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1493: COVID-19 RELATED THROMBOTIC, CARDIOVASCULAR, AND RENAL COMPLICATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM AN INTERNATIONAL REGISTRY
por: Spiera, Emily, et al.
Publicado: (2022)

Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis
por: Kumar, Anand, et al.
Publicado: (2020)

Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
por: Alexander, James L., et al.
Publicado: (2022)

Su1482: SCOUT IBD: SURVEILLANCE OF COVID-19 IMPACT ON LONG-TERM OUTCOMES IN IBD
por: Hong, Simon J., et al.
Publicado: (2022)

Su1483: COVID-19 VACCINES ARE HIGHLY EFFECTIVE IN PATIENTS WITH IBD: OUTCOMES FROM THE SCOUT IBD COHORT
por: Hong, Simon J., et al.
Publicado: (2022)

Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
por: Vuitton, Lucine, et al.
Publicado: (2022)

Su1486: INCREASED RISK OF VENOUS THROMBOEMBOLISM AMONG HOSPITALIZED INFLAMMATORY BOWEL DISEASE PATIENTS WITH EXPOSURE TO SEVERE ACURE RESPIRATORY SYNDROME CORONAVIRUS 2
por: Kumar, Rashmi, et al.
Publicado: (2022)

Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
por: Lelong, Margaux, et al.
Publicado: (2022)

Su093 GUT-BRAIN AXIS AND IRRITABLE BOWEL SYNDROME DURING SARS COV-2 PANDEMIC. A SURVEY BASED STUDY.
por: Piskorz, Maria, et al.
Publicado: (2021)

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

Su1481: IMPACT OF IMMUNOSUPPRESSIVE THERAPIES ON ANTIBODY DECAY FOLLOWING MRNA VACCINATION TO SARS-COV-2 IN A PROSPECTIVE COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES
por: Deepak, Parakkal, et al.
Publicado: (2022)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Fr501 BIOLOGICS AND COVID-19 OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Weissman, Simcha, et al.
Publicado: (2021)

Su1065: INCREASED INTEREST IN WEIGHT LOSS AND BARIATRIC INTERVENTIONS DURING THE COVID-19 PANDEMIC: AN ANALYSIS OF INTERNET SEARCH QUERIES
por: Rajan, Anjana, et al.
Publicado: (2022)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Sa1053: OUTCOMES OF HOSPITALIZED COVID-19 PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONAL DATABASE STUDY
por: Melquist, Stephanie J., et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Fr500 COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Tripathi, Kartikeya, et al.
Publicado: (2021)

Fr502 INFLAMMATORY BOWEL DISEASE AND COVID-19: A LARGE INTEGRATED HEALTHCARE EXPERIENCE
por: Tashjian, Vartan C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7hhs6c7sud0nc2u3d5g88j7k2o